Research Article
Antithrombotic Therapy in Patients with Acute Coronary Syndrome in the Intermountain Heart Collaborative Study
Table 2
Patient characteristics by in-hospital AT therapy.
| | | No Antiplatelet | Single antiplatelet | Dual antiplatelet | | | No AC | AC | No AC | AC | No AC | AC | | | | | | | | |
| | Age (mean ± std) | 63.8 ± 13.48 | 63.1 ± 15.25 | 68.4 ± 16.87 | 64.7 ± 12.50 | 66.9 ± 10.93 | 64.1 ± 12.25 | | Male | 37.5% | 67.9% | 58.3% | 68.4% | 80.0% | 74.2% | | Caucasian | 87.5% | 91.7% | 91.7% | 88.2% | 100.0% | 89.7% | | Body Mass Index (mean ± std) | 29.5 ± 4.18 | 28.9 ± 6.29 | 27.4 ± 5.93 | 30.0 ± 10.04 | 32.2 ± 7.44 | 29.7 ± 7.55 | | Family history of early CVD | 50.0% | 36.7% | 33.3% | 39.7% | 40.0% | 45.3% | | Smoking history | 25.0% | 13.8% | 16.7% | 15.2% | 10.0% | 16.4% | | Prior MI | 25.0% | 7.3% | 0.0% | 13.8% | 0.0% | 17.5% | | Comorbidities | | | | | | | | COPD | 0.0% | 8.3% | 25.0% | 7.6% | 0.0% | 7.5% | | CVA | 0.0% | 5.5% | 8.3% | 5.1% | 0.0% | 3.8% | | Diabetes | 12.5% | 21.1% | 16.7% | 26.5% | 30.0% | 25.9% | | Heart failure | 25.0% | 25.7% | 33.3% | 31.8% | 10.0% | 22.6% | | Hypercoagulability | 0.0% | 0.9% | 0.0% | 0.4% | 0.0% | 0.1% | | Hyperlipidemia | 37.5% | 57.8% | 58.3% | 60.3% | 50.0% | 66.2% | | Hypertension | 50.0% | 65.1% | 75.0% | 62.6% | 90.0% | 66.0% | | Major bleeding or ICH | 0.0% | 2.8% | 8.3% | 2.8% | 0.0% | 1.9% | | Renal failure | 0.0% | 7.3% | 0.0% | 8.2% | 20.0% | 6.4% | | Valve disease | 0.0% | 11.9% | 0.0% | 9.2% | 10.0% | 9.0% | | VTE | 0.0% | 9.2% | 0.0% | 9.1% | 10.0% | 5.7% | | AF | | | | | | | | No AF | 75.0% | 81.7% | 58.3% | 72.5% | 90.0% | 85.1% | | Prior but not current | 12.5% | 6.4% | 16.7% | 3.8% | 0.0% | 4.2% | | Prior and current | 0.0% | 8.3% | 0.0% | 6.6% | 10.0% | 4.2% | | New onset | 12.5% | 3.7% | 25.0% | 17.1% | 0.0% | 6.5% | | Charlson Comorbidity Index (mean ± std) | 5.6 ± 3.74 | 6.0 ± 3.72 | 8.2 ± 5.02 | 6.5 ± 4.05 | 6.6 ± 5.60 | 5.9 ± 3.82 | | Mechanical value | 0.0% | 0.0% | 0.0% | 0.5% | 0.0% | 0.2% | | Presentation | | | | | | | | Unstable angina | 25.0% | 65.1% | 41.7% | 44.2% | 20.0% | 40.0% | | STEMI | 0.0% | 9.2% | 16.7% | 8.2% | 30.0% | 14.6% | | Non-STEMI | 75.0% | 25.7% | 41.7% | 47.6% | 50.0% | 45.4% | | In-hospital procedures | | | | | | | | PCI without stent | 0.0% | 4.6% | 0.0% | 6.1% | 0.0% | 5.3% | | PCI with bare metal stent | 0.0% | 8.3% | 0.0% | 2.5% | 20.0% | 27.2% | | PCI with drug eluting stent | 0.0% | 14.7% | 0.0% | 6.8% | 60.0% | 58.4% | | CABG | 0.0% | 11.0% | 8.3% | 39.0% | 0.0% | 2.9% | | Number of vessels with CAD | | | | | | | | None | 50.0% | 33.0% | 33.3% | 22.4% | 10.0% | 3.9% | | Single | 12.5% | 25.7% | 16.7% | 18.7% | 50.0% | 42.0% | | Multiple | 37.5% | 41.3% | 50.0% | 58.9% | 40.0% | 54.1% | | Hospital length of stay (mean ± std) | 10.8 ± 7.14 | 4.8 ± 6.46 | 3.0 ± 1.91 | 7.3 ± 7.86 | 2.2 ± 1.40 | 3.4 ± 4.54 |
|
|
Note: AC: anticoagulant; CVD: cardiovascular disease; MI: myocardial infarction; COPD: chronic obstructive pulmonary disease; CVA: cerebral vascular accident; ICH: intracranial hemorrhage; VTE: vascular thrombus event; AF: atrial fibrillation; STEMI: ST elevated myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graph; CAD: coronary artery disease.
|
